Delmarva Foundation formally held two contracts with the Centers for Medicare & Medicaid Services (CMS) as federally-designated Quality Improvement Organizations (QIOs) for the state of Maryland and the District of Columbia. We held this distinction for Maryland from 1973-2014, when we began as a Professional Standards Review Organization (PSRO), and for the District of Columbia from 1984-2014, when we held the contract for the 1st Scope of Work as a Peer Review Organization (PRO).

In May 2014, CMS announced changes to its QIO program structure, including a multistate regional approach to replace state-specific QIOs for quality improvement work, designated the Quality Innovation Network Quality Improvement Organization (QIN-QIO) Program.

Beginning August 1, 2014 Delmarva Foundation became part of the Atlantic Quality Improvement Network (AQIN) QIN-QIO, which includes the New York and South Carolina QIOs. The AQIN provides targeted technical assistance and engages providers and stakeholders in improvement initiatives through numerous Learning and Action Networks. The networks serve as information hubs to monitor data, engage relevant organizations, facilitate learning and sharing of best practices, reduce disparities and elevate the voice of the patient.

As a member of the AQIN, Delmarva Foundation is dedicated to transforming health care and health care outcomes for patients in the District of Columbia.

Our work for the next five years will focus on several key issues including:

  • Improving cardiac health and reducing cardiac health care disparities
  • Reducing disparities in diabetes care
  • Improving prevention efforts through meaningful use of health information technology
  • Reducing infections in hospitals
  • Reducing harm in nursing homes
  • Assisting physicians and hospitals with quality reporting
  • Helping communities improve the coordination of health care for patients to help reduce unnecessary hospital readmissions
  • Reducing adverse drug events (ADEs) across the continuum of care, with specific attention on high risk medications; anticoagulants, diabetes agents, and opioids